MetaVia Inc. — Director's Dealing 2016

Aug 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-10

Reporting Person: Bisgaier Charles PhD (Director, Chair & Chief Scientific Off., 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-10	Common Stock	C	59561	—	Acquired	59561	Indirect
2016-08-10	Common Stock	J	6515	$6.7059	Acquired	66076	Indirect
2016-08-10	Common Stock	C	16144	$6.7059	Acquired	82220	Indirect
2016-08-10	Common Stock	C	19228	$6.7059	Acquired	19228	Indirect
2016-08-10	Common Stock	P	51750	$10.00	Acquired	1244440	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-10	Series A Convertible Preferred Stock	$	C	59561	Disposed		Common Stock (59561)	Indirect
2016-08-10	8% Convertible Subordinated Promissory Notes	$6.7059	C		Disposed		Common Stock (16144)	Indirect
2016-08-10	8% Convertible Subordinated Promissory Notes	$6.7059	C		Disposed		Common Stock (19228)	Indirect

Footnotes

F1: The Series A Convertible Preferred Stock converted into shares of common stock, par value $0.001 per share (the "Common Stock"), of Gemphire Therapeutics Inc. (the "Company") on a one-for-one basis immediately prior to the closing of the Company's initial public offering and had no expiration date.

F2: These shares are indirectly owned by the reporting person as trustee of The Charles L. Bisgaier Trust.

F3: Represents shares of Common Stock issued for payment of accrued dividends on the Series A Convertible Preferred Stock.

F4: The notes were issued in the original principal amount of $100,000. The outstanding principal and $8,263 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.

F5: The notes were issued in the original principal amount of $125,000. The outstanding principal and $3,945 of accrued interest on the notes automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.